Morphine and morphine-6-glucuronide concentrations and their correlation with pain responses
|
|
- Roland Carson
- 5 years ago
- Views:
Transcription
1 Archives of Perinatal Medicine 16(2), 92-96, 2010 ORGNAL PAPER Morphine and morphine-6-glucuronide concentrations and their correlation with pain responses JOANNA RÓŻYCKA 1, JANUSZ GADZNOWSK 1, DHARMAPUR VDYASAGAR 2, MAREK CHUCHRACK 3 Abstract The aim of the study was to assess morphine and its metabolite morphine-6-glucuronide (M6G) serum concentrations after continuous morphine infusion during first days of life, in preterm neonates requiring mechanical ventilation. We also examined correlation between morphine, its metabolite and pain scores. Fourteen preterm neonates with a mean birth weight of 1196 g (range g) and mean of 29 weeks (range weeks) gestational age were randomly assigned to the study group. They received morphine for 1 to 5 days (100 mg/kg over 30 minutes followed by 20 mg/kg/h). Blood samples were obtained from neonates at 0, 30 minutes, 6 and 24 hours after the start of morphine infusion and 24 hours after discontinuation of infusion. The pain responses were assessed using two scales Premature nfant Pain Profile (PPP) and Comfort Scale (CS) at 6 and 24 hours. M6G was found in all samples, even after 30 minutes of morphine infusion. n most samples M6G concentration exceeded morphine concentration. Mean ± SD morphine clearance was 5.5 ± 3.0 ml/min/kg. There was a significant negative correlation between morphine plasma concentration and Comfort Scale scores at 6 hour of the study (r = 0.72, p = 0.003). There was no correlation between M6G and pain scores. Clearance value of morphine was similar to values published by other authors. Finding correlation only between morphine concentration and CS at 6 th hour of the study confirms complex problem of pain assessment. Key words: morphine, morphine-6-glucuronide, pain ntroduction Pain is an unpleasant sensory and emotional experience connected with actual or potential tissue damage [1]. Before mid-1980s it was believed that newborn infants did not feel pain and consequently the use of analgesics in neonatal units was limited. Although in 1985 intraoperative anesthesia was a routine in adults, only 23% of preterm infants undergoing patent ductus arteriosus ligation received adequate anesthesia [2]. t has taken scientists and doctors a long time to accept what parents have always known that the infant can feel pain [3]. Preterm newborns and critically ill term newborns admitted to the intensive care unit are subjected to multiple diagnostic and therapeutic events that cause pain and discomfort. The younger the gestational age of the neonate, the more likely they are to have an increased number of procedures [4]. There are speculations that painful stimuli are followed for prolonged periods in which non noxious procedures (handling, physical examination, nursing procedures, etc.) may be perceived as chronic painful stimulation [5]. To obviate the effects of pain many analgesics have been used. Morphine is one of the most popular of them Morphine is widely in neonatal intensive care units now. There is, however, some concern regarding appropriate dosing, its analgesic effect and possible side effects in newborns [6-8]. Large variations in the pharmacokinetic properties of morphine have been found in term and preterm infants. That s why recently more studies have concentrated on the pharmacokinetics of the opioid analgesics in infants and neonates [9-12]. Appropriate morphine doses and desired serum levels in preterm and newborn infants providing analgesia are still being investigated. Because of its wide usage in the preterm and term infants the pharmacology and metabolic pathway need to be well understood. Morphine undergoes glucuronide conjugation in the liver to two metabolites: morphine-3- glucuronide (M3G) and morphine-6-glucuronide (M6G), which are subsequently excreted by the kidney. Whilst M3G appears to be an opiate antagonist, M6G has potent analgesic properties [13, 14]. There is no information regarding the role of morphine and its components on the analgesic effects in the newborn We conducted a study to assess morphine and its metabolite concentrations, to assess morphine clearance and to find correlation between morphine and its metabolite M6G and pain scores. 1 Department of Neonatology, University of Medical Sciences, Poznań, Poland 2 Division of Neonatology, University of llinois at Chicago, USA 3 Department of Mother and Child Health, University of Medical Sciences, Poznań, Poland
2 Morphine and morphine-6-glucuronide concentrations and their correlation with pain responses 93 Material The study protocol was approved by the Ethics Committee of the University of Medical Sciences in Poznań. 14 preterm, mechanically ventilated newborns at first day of life, of gestational age 26 to 33 weeks (29 ± 2 SD) and birth weight 780 to 1760 grams (1196 ± 277 SD) were studied. All of them had respiratory distress and received surfactant. Neonates born with major congenital anomalies, birth asphyxia (5 minute Apgar score < 4 points or umbilical vessels ph < 7.0) [15] maternal opioid addiction and neonates receiving muscle relaxants were excluded from the study. Methods After written informed consent from the parents, eligible infants received a loading dose of morphine of 100 μg/kg over 30 minutes, followed by a continuous infusion at a constant rate of 20 μg/kg/hour for at least 24 hours, up to 5 days. Morphine was diluted in 5% glucose and given at 0.5 ml/hour rate. Blood samples before morphine administration were obtained and 1 ml at 30 minutes and at 6 and 24 hours after morphine dose from umbilical catheter. Additional sample was obtained 24 hours after morphine discontinuation. Only 4 to 5 samples were taken from any one infant to minimize the loss of blood volume. Serum was separated and stored at 70 C for later analysis. Level of sedation was assessed by the Comfort Scale CS [16] and responses to pain were measured by the Premature nfant Pain Profile (PPP) score [4,17]. These measurements were obtained before starting the study drug infusion, at 6 and 24 hours after morphine administration. All newborns received regular monitoring of blood pressure, heart rate, ventilator rate and diuresis. Analytical methods Morphine and morphine-6-glucuronide (M6G) were measured in plasma using modified radioimmunoassay (RA) with the use of antibodies [18]. Lower limit of detection for morphine and M6G was 0.67 ng/ml and 0.13 ng/ml respectively. The coefficient of variation in the range of the analyses was for morphine 10.4% and 6,1% for M6G. Statistical analysis The data were calculated by means of a computer program STATSCA v Data are presented as mean values±sd or as medians and interquartile ranges, when appropriate. The relationships between morphine clearance and gestational age and birthweight were analyzed with Pearson s correlation coefficient. Relationship between morphine and M6G concentration pain scales were investigated using Spearman s rank correlation analysis. A p value of < 0,05 was considered to be statistically significant. Results The median postnatal age of the studied patients was 4 hours (range 2-20) at the start of the loading dose, and the median duration of morphine administration was 1 day (range1 to 5 days). Mean (SD) plasma concentration of morphine and M6Gs are shown in Table 1 and Fig 1. Table1. Mean ± SD plasma morphine and M6G concentrations at first day of life (at 0, 0.5, 6, 24 hours) after morphine infusion and 24 hours after discontinuation of morphine infusion Morphine (ng/ml) Mean ± SD Median Minimum Maximum Number of samples (n) 0 hour hours 23.8 ± hours 51.4 ± hours 84.3 ± hours after discontinuation 44.0 ± M6G (ng/ml) Mean ± SD Median Minimum Maximum Number of samples (n) 0.5 hours 47.4 ± hours 53.6 ± hours 96.8 ± hours after discontinuation 87.0 ±
3 94 J.Różycka, J.Gadzinowski, D.Vidyasagar, M.Chuchracki ) 120 Serum concentration (ng/ml n =14 n =14 n =7 n =7 n =14 n =14 Morphine M6G Time (hours) Fig.1. Mean plasma morphine and M6G concentrations on first day of life (at 0, 0.5, 6, 24 hours) after morphine infusion and 24 hours after discontinuation of morphine infusion n =12 24 hours after discontinuation n =12 24 hours after discontinuation Morphine concentration at 6th hour of the study [ng/ml] CS scores at 6 hour of the study Fig. 2. Negative correlation between morphine concentration and CS scores at 6 hour of the study (Spearman s correlation rate, r = 0.72, p = ) Table 2. Clearance values for all newborns, calculated from morphine plasma concentration at 24 hours of the infusion No. Weeks of gestation [weeks] Birth weight [g] Morphine concentration at 24 hours of drug infusion [ng/ml] Clearance [ml/min/kg] Mean ± SD 29 ± ± ± ± 3.0 M6G was found in all samples, even after 30 minutes of morphine infusion. n most samples M6G concentration exceed morphine concentration. Morphine clearance values for all infants are shown in Table 2. The values were calculated from morphine plasma concentration at 24 hours of study drug infusion. Mean clearance value for group was 5.5 ± 3.0 ml/min/kg. There was no statistical correlation between morphine clearance and week of gestation or birth weight (Spearman rank correlation, respectively r = 0.09; r = 0.04, p > The correlation between morphine and M6G concentration and PPP and CS scores was analyzed. The only significant correlation found was a negative correlation between morphine concentration and CS scores at 6 hour of the study (Spearman s correlation rate, r = 0,72, p = 0,0032) (Fig. 2). Discussion Morphine metabolism and pharmacokinetics have been widely studied in adults and children, but data on preterm newborns are limited [19]. Most studies were performed on a small number of newborns and few examined preterm newborns. We tried to find correlation between morphine and M6G plasma concentrations and their effect on pain res-
4 Morphine and morphine-6-glucuronide concentrations and their correlation with pain responses 95 ponses. The correlation between morphine concentration and pain scale scores was achieved only for Comfort Scale at 6 th hour of morphine infusion. Studies performed in older children and adults did not show correlation between morphine concentration and pain responses [20, 21]. Scott at al. [9] analyzed the group of preterm newborns, requiring mechanical ventilation using Neonatal Facial Coding System. n their although morphine showed to lower the pain responses, no correlation between morphine concentration and changes in face mimic were found. Chay et al. examined 19 term and preterm newborns and found that the sedative properties of morphine were achieved when morphine plasma concentration was 125 ng/ml [22]. Such a high level was found only in 2 newborns at 24 hours of drug infusion in our study. According to other studies examining morphine effect on lowering pain responses adequate morphine concentrations ranged between 20 to 65 ng/ml [22-24]. n our study 79% of newborns exceeded morphine concentration of 20 ng/ml at 6 th hour of morphine infusion. t was assumed that analgesic effect of morphine is achieved with lower concentrations than Chay proved as causing sedation effect. Analyzing therapeutic effect of morphine we have to take into consideration also its metabolites. n adults and children M6G concentration exceeds morphine concentration. Glucuronization is slower in preterm newborns, because of liver immaturity [25, 26]. n preterm neonates M3G levels were higher than M6G levels, and in some studies M6G wasn t detected at all [22]. n our study M6G was detected in all samples, even after 30 minutes of morphine infusion. n most samples (57% of samples) M6G concentration exceeded morphine concentration. No correlation between M6G concentration and pain scales scores was found. n this study mean morphine clearance value (mean ± SD) was 5.5 ± 3.0 ml/min/kg. t was calculated based on morphine concentration at 24 hour of morphine infusion. To minimize the blood volume requirement per patient and because of short time of morphine infusion (often 24 hours) it wasn t possible to calculate morphine concentration at steady-state. t was assumed that steady-state was achieved at 24 hours of study drug infusion. According to Saarenmaa study, some newborns achieve steady-state morphine concentration on the second day of infusion [12]. Because of these limitations, clearance value is approximated. t is comparable to clearance values reported in earlier studies. The reported values of plasma clearance in preterm neonates range from 2.27 ml/kg/min [9] to 4.7 ml/kg/min [27] and were lower comparing with term newborns. n term neonates, the reported values range from 6.3 to 20.1 ml/kg/min [27, 28]. Our estimation of morphine clearance as 5.5 ml/ kg/min supports the belief that the elimination rate of morphine is reduced in preterm infants. Some studies showed correlation between morphine clearance and week of gestation and birth weight [12, 22, 29]. They showed that the more mature and higher the birth weight, the higher is morphine clearance. Probably the small number of patients and the range of gestational age of patients participating in our study, did not show such correlation with gestational age or weight. Barrett et al had similar problem in their study [30]. Unsatisfactory knowledge on morphine metabolism causes the risk of its side effects. Newborns are the only patients that don t receive analgesia and sedation routinely after intubation. Systemic research investigations on large number of newborns assessing morphine and its metabolites concentrations and their influence on pain control and sedation are needed. Finding correlation only between morphine concentration and CS at 6 th hour of the study confirms complex problem of providing analgesia and pain assessment in preterm neonates. Our data suggest wide variability in the pharmacokinetic properties of morphine in preterm patients. References [1] Merskey H. (1991) The definition of pain. Eur. J. Psychiatry 6: [2] Anand K.J., Aynsley Green A. et al. (1985) Metabolic and endocrine effects of surgical ligation of patent ductus arteriosus in the human preterm neonate: are there implications for improvement of postoperative outcome? Mod. Probl. Pediatr. 23: 143. [3] Choonara. (1992) Management of pain in newborn infants. Sem. Per. 16 (1): [4] Ballantyne M. (1999) Validation of the premature infant pain profile in the clinical setting. Clin. J. Pain. 15 (4): [5] Anand K.J.S. (1993) Relationships between stress responses and clinical outcome in newborns, infants and children. Crit. Care Med. 21: S [6] Carbajal R., Lenclen R., Jugie M. et al. (2005) Morphine does not provide adequate analgesia for acute procedural pain among preterm neonates. Pediatrics. 115 (6): [7] Bhandari V., Bergqvist L.L., Kronsberg S.S. et al. (2005) NEOPAN Trial nvestigators Group. Morphine administration and short-term pulmonary outcomes among ventilated preterm infants. Pediatrics 116 (2): [8] Hall R.W., Kronsberg S.S., Barton B.A. et al. (2005) NEO- PAN Trial nvestigators Group. Morphine, hypotension,
5 96 J.Różycka, J.Gadzinowski, D.Vidyasagar, M.Chuchracki and adverse outcomes among preterm neonates: who's to blame? Secondary results from the NEOPAN trial. Pediatrics 115 (5): [9] Scott C.S., Riggs K.W., Ling E.W. et al. (1999) Morphine pharmacokinetics and pain assessment in premature newborns. J. Pediatr. 135: [10] Barrett D.A., Barker D.P., Rutter N. et al. (1996) Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. Br. J. Clin. Pharmacol. 41 (6): [11] Bouwmeester N.J., Anderson B.J., Tibboel D. et al. (2004) Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. Br. J. Anaesth. 92 (2): [12] Saarenmaa E., Neuvonen P.J., Rosenberg P. et al. (2000) Morphine clearance and effects in newborn infants in relation to gestational age. Clin. Pharmacol. Ther. 68: [13] Osborne R., Joel S., Trew D., et al. (1990) Morphine and metabolite behaviour after different routes of morphine administaration: demonstration of of the importance of the active metabolite morphine-6-glucuronide. Clin. Pharmacol. Ther. 47: [14] Smith M.T., Watt J.A., Cramond T. (1990) Morphine-3-glucuronide a potent antagonist of morphine analgesia. Life Sci. 47: [15] Committee on Fetus and Newborn, American Academy of Pediatrics, and Committee on Obstetric Practice, American College of Obstetricians and Gynecologists. (1996) Use and abuse of the Apgar score. Pediatrics 98: [16] Wielenga J.M., De Vos R., de Leeuw R. et al. (2004) COMFORT scale: a reliable and valid method to measure the amount of stress of ventilated preterm infants. Neonatal Netw. 23: [17] Stevens B., Johnston C., Petryshen P. et al. (1996) Premature nfant Pain Profile: development and initial validation. Clin. J. Pain. 12: [18] Chapman D.J., Joel S.P., Aherne G.W. (1994) Evaluation of a differential radioimmunoassay technique for the determination of morphine and morphine-6-glucuronide in human plasma. J. Pharm. Biomed. Anal. 12 (3): [19] Kart T., Christrup L.L., Rasmussen M. (1997) Recommended use of morphine in neonates, infants and children based on a literature review; part 1: pharmacokinetics. Pediatr. Anasth. 7: [21] Dahlstrom B., Bolme P., Feychting H. et al. (1979) Morphine kinetics in children. Clin. Pharmacol. Ther. 26: [21] Lynn A.M., Opheim K.E., Tyler D.C. et al. (1984) Morphine infusion after pediatric cardiac surgery. Crit. Care Med. 12: [22] Chay P.C., Duffy B.J., Walker J.S. (1992) Pharmacokinetic-pharmacodynamic relationships of morphine in neonates. Clin. Pharmacol. Ther. 51: [23] Berkowitz B.A., Ngai S.H., Yang J.C. et al. (1975) The disposition of morphine in surgical patients. Clin. Pharmacol. Ther. 17: [24] Olkkola K.T., Maunuksela E.L., Korpela R. et al. (1988) Kinetics and dynamics of postoperative intravenous morphine in children. Clin. Pharmacol. Ther. 44: [25] Choonara.A., McKay P., Hain R. et al. (1989) Morphine metabolism in children. Br. J. Clin. Pharmacol. 28: [26] Pacifici G.M., Sawe J., Kager L. et al. (1982) Morphine glucuronidation in human fetal and adult liver. Eur. J. Clin. Pharmacol. 22: [27] Choonara., Lawrence A., Michalkiewicz A. et al. (1992) Morphine metabolism in neonates and infants. Br. J. Clin. Pharmacol. 34: [28] Lynn A.M., Slattery J.T. (1987) Morphine pharmacokinetics in early infancy. Anesthesiology 66: [29] Bhat R., Chari G., Gulati A. et al. (1990) Pharmacokinetics of a single dose of morphine in preterm infants during the first week of life. J. Pediatr. 117: [30] Barrett D.A., Elias-Jones A.C., Rutter N. et al. (1991) Morphine kinetics after diamorphine infusion in premature neonates. Br. J. Clin. Pharmacol. 32 (1): J J. Różycka Department of Neonatology University of Medical Sciences Poznań, ul. Polna 33, Poland
Morphine pharmacokinetics and pain assessment in
ORIGINAL ARTICLES Morphine pharmacokinetics and pain assessment in premature newborns Christy S. Scott, PharmD, K. Wayne Riggs, PhD, Emily W. Ling, MD, Colleen E. Fitzgerald, RN, Marilyn L. Hill, PhD,
More informationP ain management of neonates admitted to neonatal
F46 ORIGINAL ARTICLE Morphine in ventilated neonates: its effects on arterial blood pressure S H P Simons, D W E Roofthooft, M van Dijk, R A van Lingen, H J Duivenvoorden, J N van den Anker, D Tibboel...
More informationSEDATION FOR SMALL PROCEDURES
SEDATION FOR SMALL PROCEDURES Sinno Simons Erasmus MC Sophia Children s Hospital Rotterdam, the Netherlands s.simons@erasmusmc.nl SEDATION in newborns How and when How to evaluate How to dose Why to use
More informationPain Management in the NICU. Tamorah Lewis MD, PhD
Pain Management in the NICU & Iatrogenic Opiate Withdrawal Tamorah Lewis MD, PhD Assistant Professor Divisions of Neonatology & Clinical Pharmacology, Toxicology and Therapeutic Innovation The Children's
More informationSWISS SOCIETY OF NEONATOLOGY. Prolonged arterial hypotension due to propofol used for endotracheal intubation in a newborn infant
SWISS SOCIETY OF NEONATOLOGY Prolonged arterial hypotension due to propofol used for endotracheal intubation in a newborn infant July 2001 2 Wagner B, Intensive Care Unit, University Children s Hospital
More informationLong term high dose morphine, ketamine and midazolam infusion in a child with burns
Br. J. clin. Pharmac. (1990), 30, 901-905 Long term high dose morphine, ketamine and midazolam infusion in a child with burns I. CEDERHOLM', M. BENGTSSON', S. BJORKMAN2, I. CHOONARA' & A. RANE3 'Department
More informationChildren are small adults and babies are young children
1 Children are small adults and babies are young children Nick Holford Dept Pharmacology & Clinical Pharmacology Brian Anderson Dept Anaesthesia & Starship Hospital University of Auckland, New Zealand
More informationBaby It Hurts. Deb Fraser, MN, RNC
Baby It Hurts Deb Fraser, MN, RNC Outline What is pain? Misconceptions about pain Problems with neonatal pain management Pain assessment Our view of pain? definitions Pain: An unpleasant sensory or emotional
More informationReview Article Clinical Pharmacology of Midazolam in Neonates and Children: Effect of Disease A Review
International Journal of Pediatrics, Article ID 309342, 20 pages http://dx.doi.org/10.1155/2014/309342 Review Article Clinical Pharmacology of Midazolam in Neonates and Children: Effect of Disease A Review
More informationAdmission/Discharge Form for Infants Born in Please DO NOT mail or fax this form to the CPQCC Data Center. This form is for internal use ONLY.
Selection Criteria Admission/Discharge Form for Infants Born in 2016 To be eligible, you MUST answer YES to at least one of the possible criteria (A-C) A. 401 1500 grams o Yes B. GA range 22 0/7 31 6/7
More informationSpecialist neonatal respiratory care for babies born preterm
National Institute for Health and Care Excellence Draft for Consultation Specialist neonatal respiratory care for babies born preterm [E] Evidence reviews for sedation and analgesia NICE guideline
More informationPediatric Drug Development Current Challenges
Pediatric Drug Development Current Challenges Robert Ward, MD, FAAP, FCP Professor Emeritus, Pediatrics Founder Univ Utah Pediatric Pharmacology Program Former Attending Neonatologist University of Utah
More informationOf the following, the BEST nutritional strategy for this infant would be to add:
NeoReviewsPlus 2009 August 09 Assessment Your Score Page 1234 5678910 My Learning Plan 1 2 3 January 09 February 09 March 09 A 700-g infant regained her birthweight 14 days after birth. She is receiving
More informationAwake regional versus general anesthesia in preterms and ex-preterm infants for herniotomy
Awake regional versus general anesthesia in preterms and ex-preterm infants for herniotomy Department of Anaesthesia University Children s Hospital Zurich Switzerland Epidemiology Herniotomy needed in
More informationPARACOD Tablets (Paracetamol + Codeine phosphate)
Published on: 22 Sep 2014 PARACOD Tablets (Paracetamol + Codeine phosphate) Composition PARACOD Tablets Each effervescent tablet contains: Paracetamol IP...650 mg Codeine Phosphate IP... 30 mg Dosage Form/s
More informationHaemodynamics of intravenous paracetamol in neonates
Haemodynamics of intravenous paracetamol in neonates Karel Allegaert, Gunnar Naulaers To cite this version: Karel Allegaert, Gunnar Naulaers. Haemodynamics of intravenous paracetamol in neonates. European
More informationAnesthetics, Local a / or Anesthesia, Epidural a / or Anesthesia, Obstetrical a / or Pain, Postoperative a / or Postpartum Period a
Appendix 1. Literature Search Databases Years Search Terms Pubmed 01/1966 1. Analgesics, Opioid a / or Opioid-related Disorders a / PsycINFO EMBASE Cochrane 09/2016 or Heroin a / or Heroin Dependence a
More informationKofinas Perinatal Providing Care to the Unborn
Alexander D. Kofinas, MD Director, Kofinas Perinatal Associate Professor, Clinical Obstetrics and Gynecology Cornell University, College of Medicine Patient instructions for the use of Indomethacin and
More informationDBL NALOXONE HYDROCHLORIDE INJECTION USP
Name of medicine Naloxone hydrochloride Data Sheet New Zealand DBL NALXNE HYDRCHLRIDE INJECTIN USP Presentation DBL Naloxone Hydrochloride Injection USP is a sterile, clear, colourless solution, free from
More informationINTRAVENOUS FLUID THERAPY
INTRAVENOUS FLUID THERAPY PRINCIPLES Postnatal physiological weight loss is approximately 5 10% in first week of life Preterm neonates have more total body water and may lose 10 15% of their weight in
More informationINTRAVENOUS FLUIDS PRINCIPLES
INTRAVENOUS FLUIDS PRINCIPLES Postnatal physiological weight loss is approximately 5-10% Postnatal diuresis is delayed in Respiratory Distress Syndrome (RDS) Preterm babies have limited capacity to excrete
More informationPOLICY and PROCEDURE
Misericordia Community Hospital Administration of Intravenous FentaNYL During Labour POLICY and PROCEDURE Labour and Delivery Manual Original Date Revised Date Approved by: Director, Women s Health, Covenant
More informationSWISS SOCIETY OF NEONATOLOGY. Peripartal management of a prenatally diagnosed large oral cyst
SWISS SOCIETY OF NEONATOLOGY Peripartal management of a prenatally diagnosed large oral cyst May 2007 2 Fontana M, Berger TM, Winiker H, Jöhr M, Nagel H, Neonatal and Pediatric Intensive Care Unit (FM,
More informationPRACTICE GUIDELINES WOMEN S HEALTH PROGRAM
C Title: NEWBORN: HYPOGLYCEMIA IN NEONATES BORN AT 35+0 WEEKS GESTATION AND GREATER: DIAGNOSIS AND MANAGEMENT IN THE FIRST 72 HOURS Authorization Section Head, Neonatology, Program Director, Women s Health
More informationClinicoetiological profile and risk assessment of newborn with respiratory distress in a tertiary care centre in South India
International Journal of Contemporary Pediatrics Sahoo MR et al. Int J Contemp Pediatr. 2015 Nov;2(4):433-439 http://www.ijpediatrics.com pissn 2349-3283 eissn 2349-3291 Research Article DOI: http://dx.doi.org/10.18203/2349-3291.ijcp20150990
More informationMORPHINE ADMINISTRATION
Introduction Individualised Administration Drug of Choice Route of Administration & Doses Monitoring of Neonates & high risk patients Team Management Responsibility Morphine Protocol Flow Chart Introduction
More informationPain Control in the NICU
Pain Control in the NICU By Robert Cicco, MD Introduction There is ample documentation in the literature that newborn infants experience pain and exhibit a variety of both physiologic and behavioral responses
More informationIntrapartum and Postpartum Management of the Diabetic Mother and Infant
Intrapartum and Postpartum Management of the Diabetic Mother and Infant Intrapartum Management Women with gestational diabetes who maintain normal glucose levels during pregnancy on diet and exercise therapy
More informationADMISSION/DISCHARGE FORM FOR INFANTS BORN IN 2019 DO NOT mail or fax this form to the CPQCC Data Center. This form is for internal use ONLY.
1 Any eligible inborn infant who dies in the delivery room or at any other location in your hospital within 12 hours after birth and prior to admission to the NICU is defined as a "Delivery Room Death."
More informationResearch Roundtable Summary
Research Roundtable Summary 10 TENTH in a Series of Seminars on MCHB-funded Research Projects Early Cortisol Deficiency and Bronchopulmonary Dysplasia October 18, 1995 Parklawn Building Potomac Conference
More informationHazards and Benefits of Postnatal Steroids. David J. Burchfield, MD Professor and Chief, Neonatology University of Florida
Hazards and Benefits of Postnatal Steroids David J. Burchfield, MD Professor and Chief, Neonatology University of Florida Disclosures I have no financial affiliations or relationships to disclose. I will
More informationSAMPLE. V.12.1 Special Report: Very Low Birthweight Neonates. I. Introduction
I. Introduction V.12.1 Special Report: Very Low Birthweight Neonates The delivery of a very low birth weight infant continues to present many challenges to families and health care providers in spite of
More informationObjectives. Nothing to Disclose No Conflicts of Interest
April 22, 2014 PCSS-MAT Webinar Lori Devlin, DO, MHA Assistant Professor- Department of Pediatrics University of Louisville School of Medicine Nothing to Disclose No Conflicts of Interest Objectives Define
More informationPharmacokinetics and pharmacology of drugs in children
Pharmacokinetics and pharmacology of drugs in children Saskia N. de Wildt Professor of Clinical Pharmacology Pediatric Intensivist-Clinical Pharmacologist Understanding pediatric PK and PD Absorption 1.
More informationDoes Targeted Neonatal Echocardiography(TnECHO) can help prevent Postoperative Cardiorespiratory instability following PDA ligation?
Does Targeted Neonatal Echocardiography(TnECHO) can help prevent Postoperative Cardiorespiratory instability following PDA ligation? Amish Jain, Mohit Sahni, Afif El Khuffash, Arvind Sehgal, Patrick J
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/22368 holds various files of this Leiden University dissertation Author: Lugt, Neeltje Margaretha van der Title: Neonatal pearls : safety and efficacy of
More informationInfection. Risk factor for infection ACoRN alerting sign with * Clinical deterioration. Problem List. Respiratory. Cardiovascular
The ACoRN Process Baby at risk Unwell Risk factors Post-resuscitation requiring stabilization Resuscitation Ineffective breathing Heart rate < 100 bpm Central cyanosis Support Infection Risk factor for
More informationBrian Anderson, Starship Hospital, Auckland, New Zealand. Shu Chin Ma, University of Auckland, New Zealand
1 Dosing in Children Holford NH, Ma SC, Anderson BJ. Prediction of morphine dose in humans. Paediatr Anaesth. 2011;10.1111/j.1460-9592.2011.03782.x. How to Reach the Target Effect Nick Holford University
More information1
1 2 3 RIFAI 5 6 Dublin cohort, retrospective review. Milrinone was commenced at an initial dose of 0.50 μg/kg/minute up to 0.75 μg/kg/minute and was continued depending on clinical response. No loading
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationSWISS SOCIETY OF NEONATOLOGY. Preterm infant with. pulmonary hypertension and hypopituitarism
SWISS SOCIETY OF NEONATOLOGY Preterm infant with pulmonary hypertension and hypopituitarism November 2007 2 Pilgrim S, Stocker M, Neonatal and Pediatric Intensiv Care Unit, Children s Hospital of Lucerne,
More informationMaternal-fetal Opiate Medical Home (MOMH) Jocelyn Davis DNP,CNM, RN, CEFMM Karen Frantz BSN, RNC
Maternal-fetal Opiate Medical Home (MOMH) Jocelyn Davis DNP,CNM, RN, CEFMM Karen Frantz BSN, RNC Objectives 1. Discuss the effects of opiate addiction on mothers and infants. 2. Discuss a Medical Home
More informationFENTANYL BY CONSTANT RATE I.V. INFUSION FOR POSTOPERATIVE ANALGESIA
Br. J. Anaesth. (1985), 5, 250-254 FENTANYL BY CONSTANT RATE I.V. INFUSION FOR POSTOPERATIVE ANALGESIA W. S. NIMMO AND J. G. TODD is a synthetic opioid analgesic 50 times more potent than morphine, with
More information5 Million neonatal deaths each year worldwide. 20% caused by neonatal asphyxia. Improvement of the outcome of 1 million newborns every year
1 5 Million neonatal deaths each year worldwide 20% caused by neonatal asphyxia Improvement of the outcome of 1 million newborns every year International Liaison Committee on Resuscitation (ILCOR) American
More informationGestational age (w eeks) Perception
Gestational age (w eeks) 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 Perception Cuteneous sensory perception MY EL INISATION Nerve tracts in the Spinal Cord and Brain Stem Internal Capsula
More informationPain relief in ventilated preterm infants during endotracheal suctioning: a randomized controlled trial
Original article Peer reviewed article SWISS MED WKLY 2008;138(43 44):635 645 www.smw.ch 635 Pain relief in ventilated preterm infants during endotracheal suctioning: a randomized controlled trial Eva
More informationPPHN (see also ECMO guideline)
Children s Acute Transport Service Clinical Guidelines PPHN (see also ECMO guideline) Document Control Information Author P Brooke E.Randle Author Position Medical Student Consultant Document Owner E.
More informationJMSCR Vol 05 Issue 07 Page July 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i7.66 To Find the Order of BCG and Hepatitis
More informationVishwanath Pattan Endocrinology Wyoming Medical Center
Vishwanath Pattan Endocrinology Wyoming Medical Center Disclosure Holdings in Tandem Non for this Training Introduction In the United States, 5 to 6 percent of pregnancies almost 250,000 women are affected
More informationStudy of renal functions in neonatal asphyxia
Original article: Study of renal functions in neonatal asphyxia *Dr. D.Y.Shrikhande, **Dr. Vivek Singh, **Dr. Amit Garg *Professor and Head, **Senior Resident Department of Pediatrics, Pravara Institute
More informationAnalgesia is a labeled indication for all of the approved drugs I will be discussing.
Comparative Opioid Pharmacology Disclosure Analgesia is a labeled indication for all of the approved drugs I will be discussing. I ve consulted with Glaxo (remifentanil), Abbott (remifentanil), Janssen
More informationCPAP failure in preterm infants: incidence, predictors and consequences
CPAP failure in preterm infants: incidence, predictors and consequences SUPPLEMENTAL TEXT METHODS Study setting The Royal Hobart Hospital has an 11-bed combined Neonatal and Paediatric Intensive Care Unit
More informationTRAINING NEONATOLOGY SILVANA PARIS
TRAINING ON NEONATOLOGY SILVANA PARIS RESUSCITATION IN DELIVERY ROOM INTRODUCTION THE GLOBAL RESUSCITATION BURDEN IN NEWBORN 136 MILL NEWBORN BABIES EACH YEAR (WHO WORLD REPORT) 5-8 MILL NEWBORN INFANTS
More informationPATENT DUCTUS ARTERIOSUS IN THE PRETERM INFANT EVIDENCE FOR & AGAINST TREATMENT
PATENT DUCTUS ARTERIOSUS IN THE PRETERM INFANT EVIDENCE FOR & AGAINST TREATMENT Dr. Youssef Abou Zanouna, FRCPI, FACC Consultant Pediatric Cardiologist King Fahd Military Medical Complex Dhahran Introduction
More informationMEASURING, MANAGING AND MITIGATING CANCER AND TREATMENT PAIN IN INFANTS: Pharmacology
MEASURING, MANAGING AND MITIGATING CANCER AND TREATMENT PAIN IN INFANTS: Pharmacology Jason T Maynes, PhD/MD Wasser Chair in Anesthesia and Pain Medicine Associate Chief of Perioperative Services (Research)
More informationPatent Ductus Arteriosus: Philosophy or Pathology?
Patent Ductus Arteriosus: Philosophy or Pathology? Disclosure Ray Sato, MD is a speaker for Prolacta Biosciences, Inc. This presentation will discuss off-label uses of acetaminophen and ibuprofen. RAY
More informationSatellite Symposium. Sponsored by
Satellite Symposium Sponsored by Management of fluids and electrolytes in the preterm infant in the first week of life Pam Cairns St Michaels Hospital Bristol Healthy, term, breast fed babies Limited intake
More informationBy: Armend Lokku Supervisor: Dr. Lucia Mirea. Maternal-Infant Care Research Center, Mount Sinai Hospital
By: Armend Lokku Supervisor: Dr. Lucia Mirea Maternal-Infant Care Research Center, Mount Sinai Hospital Background My practicum placement was at the Maternal-Infant Care Research Center (MiCare) at Mount
More informationHypoglycaemia of the neonate. Dr. L.G. Lloyd Dept. Paediatrics
Hypoglycaemia of the neonate Dr. L.G. Lloyd Dept. Paediatrics Why is glucose important? It provides 60-70% of energy needs Utilization obligatory by red blood cells, brain and kidney as major source of
More informationComparison of Two Phototherapy Methods (Prophylactic vs Therapeutic) for Management of Hyperbilirubinemia in Very Low Birth Weight Newborns
Original Article Iran J Pediatr Dec 2011; Vol 21 (No 4), Pp: 425-430 Comparison of Two Phototherapy Methods (Prophylactic vs Therapeutic) for Management of Hyperbilirubinemia in Very Low Birth Weight Newborns
More informationNoah Hillman M.D. IPOKRaTES Conference Guadalajaira, Mexico August 23, 2018
Postnatal Steroids Use for Bronchopulmonary Dysplasia in 2018 + = Noah Hillman M.D. IPOKRaTES Conference Guadalajaira, Mexico August 23, 2018 AAP Policy Statement - 2002 This statement is intended for
More informationObjectives. Birth Depression Management. Birth Depression Terms
Objectives Birth Depression Management Regional Perinatal Outreach Program 2016 Understand the terms and the clinical characteristics of birth depression. Be familiar with the evidence behind therapeutic
More informationThe Fetal Cardiology Program
The Fetal Cardiology Program at Texas Children s Fetal Center About the program Since the 1980s, Texas Children s Fetal Cardiology Program has provided comprehensive fetal cardiac care to expecting families
More informationMedication for the Treatment of Addiction (MAT)
Medication for the Treatment of Addiction (MAT) Karol Kaltenbach, PhD Emeritus Professor of Pediatrics Sidney Kimmel Medical College at Thomas Jefferson University Terminology: Words Matter Medication
More informationMedications & The ECMO Effect
Medications & The ECMO Effect B A N K E A Y A N L E K E, M P H A R M, M P H C L I N I C A L P H A R M A C I S T S H E I K H K H A L I F A H O S P I T A L Objectives Revise the Principles of ECMO (extracorporeal
More informationPharmacogenetics of Codeine. Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA
Pharmacogenetics of Codeine Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA 1 Codeine Overview Naturally occurring opium alkaloid Demethylated to morphine for analgesic effect
More informationPRODUCT MONOGRAPH. Naloxone Hydrochloride. 0.4 mg/ml. Opioid Antagonist
PRODUCT MONOGRAPH Pr NALOXONE HYDROCHLORIDE INJECTION USP Naloxone Hydrochloride 0.4 mg/ml Opioid Antagonist Teligent OÜ Akadeemia tee 21/5 Tallinn, Estonia 12618 Date of Revision: August 25, 2016 Distributed
More informationNeonatal Abstinence: The epidemic Its Impact on All of Us
Neonatal Abstinence: The epidemic Its Impact on All of Us Michelle Bode MD, MPH Neonatologist Crouse Hospital Assistant Professor Pediatrics SUNY Upstate Objectives & Disclosure Statement 1) The participant
More informationResearch Article Timing of Caffeine Therapy and Neonatal Outcomes in Preterm Infants: A Retrospective Study
International Pediatrics Volume 2016, Article ID 9478204, 6 pages http://dx.doi.org/10.1155/2016/9478204 Research Article Timing of Caffeine Therapy and Neonatal Outcomes in Preterm Infants: A Retrospective
More informationNEONATOLOGY Healthy newborn. Neonatal sequelaes
NEONATOLOGY Healthy newborn. Neonatal sequelaes Ágnes Harmath M.D. Ph.D. senior lecturer 11. November 2016. Tasks of the neonatologist Prenatal diagnosed condition Inform parents, preparation of necessary
More informationInteraction between Sedation and Weaning: How to Balance Them? Guillermo Castorena MD Fundacion Clinica Medica Sur Mexico
Interaction between Sedation and Weaning: How to Balance Them? Guillermo Castorena MD Fundacion Clinica Medica Sur Mexico Balance is not that easy! Weaning Weaning is the liberation of a patient from
More informationSurgical Care at the District Hospital. EMERGENCY & ESSENTIAL SURGICAL CARE
Surgical Care at the District Hospital 1 14 Practical Anesthesia Key Points 2 14.1 General Anesthesia Have a clear plan before starting anesthesia Never use an unfamiliar anesthetic technique in an emergency
More informationName and title of the investigators responsible for conducting the research: Dr Anna Lavizzari, Dr Mariarosa Colnaghi
Protocol title: Heated, Humidified High-Flow Nasal Cannula vs Nasal CPAP for Respiratory Distress Syndrome of Prematurity. Protocol identifying number: Clinical Trials.gov NCT02570217 Name and title of
More informationPerioperative Pain Management
Perioperative Pain Management Overview and Update As defined by the Anesthesiologist's Task Force on Acute Pain Management are from the practice guidelines from the American Society of Anesthesiologists
More information1 University of Kansas School of Medicine-Wichita, Department of Pediatrics 2 Wesley Medical Center, Department of Neonatology
Impact of on Very Low Birth Weight Infants Siddharthan Sivamurthy, M.D. 1, Carolyn R. Ahlers-Schmidt, Ph.D. 1, Katherine S. Williams, M.Ed. 1, Jared Shaw 2, Paula Delmore, M.S.N. 2, Barry T. Bloom, M.D.
More informationPain and Sedation in the NICU Dennis E. Mayock and Christine A. Gleason. DOI: /neo.14-1-e22
Article from NeoReviews, American Academy of Pediatrics, Volume 14, (2013), pages e22-e31 License No. 3256701047960 Pain and Sedation in the Dennis E. Mayock and Christine A. Gleason Neoreviews 2013;14;e22
More informationAn Overview of Bronchopulmonary Dysplasia and Chronic Lung Disease in Infancy
An Overview of Bronchopulmonary Dysplasia and Chronic Lung Disease in Infancy Housekeeping: I have no financial disclosures Learning objectives: Develop an understanding of bronchopulmonary dysplasia (BPD)
More informationLigation of patent ductus arteriosus in low birth weight premature infants: timing for intervention and effectiveness of bed-side surgery
Metin et al. Journal of Cardiothoracic Surgery 2012, 7:129 RESEARCH ARTICLE Open Access Ligation of patent ductus arteriosus in low birth weight premature infants: timing for intervention and effectiveness
More informationSTARSHIP WITHDRAWAL OF ANALGESIA AND SEDATION
STARSHIP WITHDRAWAL OF ANALGESIA AND SEDATION Patients receiving analgesia and/or sedation for longer than 5-7 days may suffer withdrawal if these drugs are suddenly stopped. To prevent this happening
More informationRecommendations for Hospital Quality Measures in 2011:
Pediatric Measures: Recommendations for Hospital Quality Measures in 2011: Based on the input of a group of healthcare stakeholders, the following new hospital measures are recommended: 1) Home Management
More informationOriginal Article. Associated Anomalies and Clinical Outcomes in Infants with Omphalocele: A Single-centre 10-year Review
HK J Paediatr (new series) 2018;23:220-224 Original Article Associated Anomalies and Clinical Outcomes in Infants with Omphalocele: A Single-centre 10-year Review YY CHEE, MSC WONG, RMS WONG, KY WONG,
More informationThe Impact of Sedation and Analgesia on the Developing Preterm Brain. Christopher McPherson, PharmD
The Impact of Sedation and Analgesia on the Developing Preterm Brain Christopher McPherson, PharmD Disclosures I have no conflicts of interest to disclose. I will be discussing off-label or unapproved
More informationUses 1,2,3 : Labeled: Prevention of respiratory distress syndrome in premature infants
Brand Name: Surfaxin Generic Name: lucinactant Manufacturer 1 : Discovery Laboratories, Inc. Drug Class 2,3 : Synthetic lung surfactant Uses 1,2,3 : Labeled: Prevention of respiratory distress syndrome
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Tralieve 50 mg/ml solution for injection for dogs (AT, BE, BG, CY, CZ, DE, EL, ES, HR, HU, IE, IT, LU, NL, PT, RO,
More informationALFENTANIL INJECTION, USP Ampul
ALFENTANIL INJECTION, USP Ampul R x only DESCRIPTION Alfentanil Injection, USP is an opioid analgesic chemically designated as N-[1-[2-(4-ethyl-4,5- dihydro-5-oxo-1h-tetrazol-1-yl)ethyl]-4-(methoxymethyl)-4-piperidinyl]-n-phenylpropanamide
More informationGuidance on competencies for Paediatric Pain Medicine reviewed 2017
Guidance on competencies for Paediatric Pain Medicine reviewed 2017 Endorsed by: Contents Introduction A: Core competencies for practitioners in Pain Medicine Page 2 4 Appendix A: Curriculum 5 B: Competencies
More informationNeonatal abstinence syndrome
PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on the Neonatal Abstinence Syndrome. These podcasts are designed to give medical students an overview of key topics in pediatrics.
More informationTheophylline for Prevention of Kidney Dysfunction in Neonates With Severe Asphyxia
kidney diseases Theophylline for Prevention of Kidney Dysfunction in Neonates With Severe Asphyxia Zia Eslami, 1 Ahmad Shajari, 2 Maryam Kheirandish, 3 Azam Heidary 4 Original Paper 1 Division of Neonates
More informationINTRODUCTION. Baltimore, Maryland 6 School of Medicine West Virginia University, Morgantown, West Virginia
The American Journal on Addictions, 27: 92 96, 2018 Copyright 2018 American Academy of Addiction Psychiatry ISSN: 1055-0496 print / 1521-0391 online DOI: 10.1111/ajad.12687 Brief Report: Treating Women
More informationCOMPARISON OF THE EFFICIENCY OF CAFFEINE VERSUS AMINOPHYLLINE FOR THE TREATMENT OF APNOEA OF PREMATURITY
CASE STUDIES COMPARISON OF THE EFFICIENCY OF CAFFEINE VERSUS AMINOPHYLLINE FOR THE TREATMENT OF APNOEA OF PREMATURITY Gabriela Ildiko Zonda 1, Andreea Avasiloaiei 1, Mihaela Moscalu 2, Maria Stamatin 1
More informationDaniel S. Sitar, BScPharm, PhD, FCP Professor Emeritus University of Manitoba Editor: Journal of Clinical Pharmacology
March 8, 2011 Daniel S. Sitar, BScPharm, PhD, FCP Email: sitar@cc.umanitoba.ca Professor Emeritus University of Manitoba Editor: Journal of Clinical Pharmacology DEFINITIONS Pain: The unpleasant sensory
More informationPrenatal Exposure to Methyldopa Leading to Hypertensive Crisis and Cardiac Failure in a Neonate
Prenatal Exposure to Methyldopa Leading to Hypertensive Crisis and Cardiac Failure in a Neonate abstract A 2-week-old infant with normal intracardiac anatomy presented to the emergency department in a
More information(1996) 2002 JAMA. IDM
Neonatal Sedation Joseph Cravero MD First Question Does Pain/Stress Control Matter? Especially in very young patients. Really? Responses to Pain - Newborns learn quickly Taddio et. al. 2002 JAMA. IDM s
More informationPatient Ductus Arteriosus (PDA)
Patient Ductus Arteriosus (PDA) WINSTON HELEN Author: Paediatric Department Document Number: STHK7026 Version: 5 Review date: 30th June 2021 The Normal Heart The Heart is made up of four chambers: the
More informationPaediatrica Indonesiana. Echocardiographic patterns in asphyxiated neonates. Maswin Masyhur, Idham Amir, Sukman Tulus Putra, Alan Roland Tumbelaka
Paediatrica Indonesiana VOLUME 49 July NUMBER 4 Original Article Echocardiographic patterns in asphyxiated neonates Maswin Masyhur, Idham Amir, Sukman Tulus Putra, Alan Roland Tumbelaka Abstract Background
More informationInfluence of Abnormal GCT with Normal or Impaired OGTT on Neonatal Outcome
JMSCR Volume 2 Issue 9 Page 2471-2482 September-2014 2014 www.jmscr.igmpublication.org Impact Factor 3.79 ISSN (e)-2347-176x Influence of Abnormal GCT with Normal or Impaired OGTT on Neonatal Outcome Authors
More informationPRODUCT MONOGRAPH NALOXONE HYDROCHLORIDE INJECTION
PRODUCT MONOGRAPH Pr NALOXONE HYDROCHLORIDE INJECTION Naloxone Hydrochloride (as dihydrate) 0.4 mg/ml 1.0 mg/ml Omega Standard Therapeutic Classification Opioid Antagonist Omega Laboratories Limited Date
More informationRemifentanil PCA In Labor
Remifentanil PCA In { Jennifer Lucero, MD Clinical Instructor UCSF Department of Anesthesia Remifentanil PCA in Discuss the Pharmokinectics of Remifentanil Review literature on the use of Remifentanil
More informationEnvironmental Variability
1 Environmental Variability Body Size, Body Composition, Maturation and Organ Function Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland 2 Objectives Understand the major sources
More information